The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 08, 2023

Filed:

Jan. 15, 2020
Applicant:

Baylor College of Medicine, Houston, TX (US);

Inventors:

Ann Marie Leen, Houston, TX (US);

Juan F. Vera, Houston, TX (US);

Assignee:

Baylor College of Medicine, Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 63/00 (2020.01); C12N 5/02 (2006.01); C12N 5/071 (2010.01); A61K 35/12 (2015.01); C12N 5/0783 (2010.01); C07K 14/715 (2006.01); A61K 39/00 (2006.01); C12N 5/078 (2010.01); C12N 15/85 (2006.01); C12N 15/63 (2006.01);
U.S. Cl.
CPC ...
A61K 35/12 (2013.01); A61K 39/00115 (2018.08); A61K 39/00117 (2018.08); A61K 39/001157 (2018.08); A61K 39/001182 (2018.08); A61K 39/001184 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001189 (2018.08); C07K 14/715 (2013.01); C12N 5/0634 (2013.01); C12N 5/0638 (2013.01); C12N 15/85 (2013.01); A61K 39/0011 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C12N 15/63 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention concerns compositions and methods related to approaches to render ineffective Th1 T cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. In particular embodiments, tumor-specific T cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a Th1 immunostimulaotyr/activating signal. In specific embodiments, the T cells employ a chimeric antigen receptor having exodomains for IL10, IL13 and/or IL4 fused with the signal transducing endodomains for IL2 and/or IL7.


Find Patent Forward Citations

Loading…